Darin Weber - ProKidney Corp VP Devel
| PROK Stock | USD 1.66 0.17 9.29% |
Insider
Darin Weber is VP Devel of ProKidney Corp
| Age | 57 |
| Address | 2000 Frontis Plaza Blvd., Winston-Salem, NC, United States, 27103 |
| Phone | 336 999 7028 |
| Web | https://www.prokidney.com |
Darin Weber Latest Insider Activity
Tracking and analyzing the buying and selling activities of Darin Weber against ProKidney Corp stock is an integral part of due diligence when investing in ProKidney Corp. Darin Weber insider activity provides valuable insight into whether ProKidney Corp is net buyers or sellers over its current business cycle. Note, ProKidney Corp insiders must abide by specific rules, including filing SEC forms every time they buy or sell ProKidney Corp'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Darin Weber over three months ago Disposition of 16412 shares by Darin Weber of ProKidney Corp at 2.5 subject to Rule 16b-3 | ||
Darin Weber over three months ago Disposition of 826 shares by Darin Weber of ProKidney Corp at 2.5 subject to Rule 16b-3 | ||
Darin Weber over six months ago Disposition of 17238 shares by Darin Weber of ProKidney Corp at 2.8203 subject to Rule 16b-3 | ||
Darin Weber over six months ago Disposition of 17238 shares by Darin Weber of ProKidney Corp at 4.0832 subject to Rule 16b-3 |
ProKidney Corp Management Efficiency
The company has return on total asset (ROA) of (0.2037) % which means that it has lost $0.2037 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3134) %, meaning that it created substantial loss on money invested by shareholders. ProKidney Corp's management efficiency ratios could be used to measure how well ProKidney Corp manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is expected to rise to 0.03 this year, although the value of Return On Tangible Assets will most likely fall to (0.08). At this time, ProKidney Corp's Total Current Liabilities is quite stable compared to the past year. Liabilities And Stockholders Equity is expected to rise to about 507.8 M this year, although the value of Change To Liabilities will most likely fall to about 843.4 K.Similar Executives
| Showing other executives | INSIDER Age | ||
| John Nuss | Ventyx Biosciences | 66 | |
| Stephen MD | Kura Oncology | 53 | |
| TaiAn Lin | Black Diamond Therapeutics | N/A | |
| Neeraj Teotia | Arcellx | 50 | |
| MA MBA | Relay Therapeutics | 48 | |
| Karen Alderete | Vaxcyte | N/A | |
| Ashish MBA | Vaxcyte | 53 | |
| Sharon Townson | Monte Rosa Therapeutics | 50 | |
| Wei MD | Erasca Inc | 54 | |
| Jeff Fairman | Vaxcyte | 61 | |
| Martin MD | Ventyx Biosciences | 49 | |
| Michelle Gilson | Arcellx | 32 | |
| Richard MD | Lyell Immunopharma | 73 | |
| Lisa TesvichBonora | Erasca Inc | N/A | |
| JD Esq | Black Diamond Therapeutics | 60 | |
| Edward MD | Third Harmonic Bio | 52 | |
| Alan Russell | Edgewise Therapeutics | 55 | |
| David MD | Erasca Inc | 41 | |
| Eric Rojas | Stoke Therapeutics | N/A | |
| Cecilia Geuijen | Merus BV | N/A | |
| Sbastien Desprez | Immunocore Holdings | N/A | |
Management Performance
| Return On Equity | -0.31 | ||||
| Return On Asset | -0.2 |
ProKidney Corp Leadership Team
Elected by the shareholders, the ProKidney Corp's board of directors comprises two types of representatives: ProKidney Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ProKidney. The board's role is to monitor ProKidney Corp's management team and ensure that shareholders' interests are well served. ProKidney Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ProKidney Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joseph MD, VP Devel | ||
| Ulrich Ernst, EVP Technology | ||
| Ashley Johns, VP Operations | ||
| Carla Poulson, Chief Officer | ||
| James CPA, Chief Officer | ||
| Richard Williams, Senior Technology | ||
| Aparna MD, VP Development | ||
| Kerry MD, VP Affairs | ||
| Bruce MD, CEO Director | ||
| Anu Biswas, Senior Operations | ||
| Mary Weger, Chief Officer | ||
| Esq JD, Chief Sec | ||
| Darin Weber, VP Devel | ||
| Deepak Jain, Chief Officer | ||
| Dr DVM, Founder Advisor | ||
| Emily Butler, Senior Biometric | ||
| Nikhil PereiraKamath, Chief Officer | ||
| Pharm MPH, Senior Relations | ||
| Libbie MD, Chief Officer | ||
| MPH MD, Senior Procedures |
ProKidney Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ProKidney Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.31 | ||||
| Return On Asset | -0.2 | ||||
| Current Valuation | (187.95 M) | ||||
| Shares Outstanding | 127.97 M | ||||
| Shares Owned By Insiders | 27.43 % | ||||
| Shares Owned By Institutions | 43.37 % | ||||
| Number Of Shares Shorted | 10.26 M | ||||
| Price To Book | 91.32 X | ||||
| EBITDA | (147.67 M) | ||||
| Net Income | (135.45 M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProKidney Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more information on how to buy ProKidney Stock please use our How to buy in ProKidney Stock guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProKidney Corp. If investors know ProKidney will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProKidney Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of ProKidney Corp is measured differently than its book value, which is the value of ProKidney that is recorded on the company's balance sheet. Investors also form their own opinion of ProKidney Corp's value that differs from its market value or its book value, called intrinsic value, which is ProKidney Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProKidney Corp's market value can be influenced by many factors that don't directly affect ProKidney Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProKidney Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if ProKidney Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProKidney Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.